Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Probing mucin-type O-linked glycosylation in living animals
2006 StandoutNobel
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Circadian oscillation of nucleotide excision repair in mammalian brain
2009 StandoutNobel
Loss of cryptochrome reduces cancer risk in p53 mutant mice
2009 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer
2014
The DNA-damage response in human biology and disease
2009 StandoutNature
Dendritic cells as therapeutic vaccines against cancer
2005
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
The biology and management of non-small cell lung cancer
2018 StandoutNature
Mucin-1 is expressed on dendritic cells, both in vitro and in vivo
2004
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Cancer immunotherapy comes of age
2011 StandoutNature
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Mucins in cancer: protection and control of the cell surface
2003
MUC1, The Renaissance Molecule
2001
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
Control of the Molecular Orientation of Membrane-Anchored Biomimetic Glycopolymers
2009 StandoutNobel
Current Developments in Cancer Vaccines and Cellular Immunotherapy
2003
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
2001
Practical Approach to Triple-Negative Breast Cancer
2017
Density Variant Glycan Microarray for Evaluating Cross-Linking of Mucin-like Glycoconjugates by Lectins
2012 StandoutNobel
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
HLA-Binding Properties of Tumor Neoepitopes in Humans
2014
Breast Cancer Treatment
2019 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Immune targeting in breast cancer.
2015
Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells
2003
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells
2006
Circadian Rhythms: Mechanisms and Therapeutic Implications
2007
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Control of skin cancer by the circadian rhythm
2011 StandoutNobel
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
2016
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal
2014
Chemically tunable mucin chimeras assembled on living cells
2015 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Interfacing Carbon Nanotubes with Living Cells
2006 StandoutNobel
Neoantigens in cancer immunotherapy
2015 StandoutScience
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
2002
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
2018
Noncovalent Cell Surface Engineering: Incorporation of Bioactive Synthetic Glycopolymers into Cellular Membranes
2008 StandoutNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Works of Vicky Jones being referenced
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
2014
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
2008
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
2004
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
1998
Therapeutic vaccines for melanoma: progress and problems
1996
The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer
2004
Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
2002
Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope
2002